GERD

7
Pipeline Programs
5
Companies
12
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
1
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 11 programs with unclassified modality

On Market (1)

Approved therapies currently available

AstraZeneca
PRILOSECApproved
omeprazole
AstraZeneca
oral1989

Competitive Landscape

5 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
9 programs
1
2
AntacidsPhase 41 trial
esomeprazolePhase 4Small Molecule1 trial
OmeprazolePhase 3Small Molecule1 trial
An Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux DiseaseN/A1 trial
Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERDN/A1 trial
+4 more programs
Active Trials
NCT01134367Completed1,000Est. Dec 2010
NCT00634023Completed500Est. May 2008
NCT00524355Completed2,717Est. Nov 2007
+6 more trials
Genomics
GenomicsUK - Oxford
1 program
1
Neobianacid®Phase 41 trial
Active Trials
NCT03238534Completed275Est. Sep 2021
E
EisaiChina - Liaoning
1 program
1
Rabeprazole sodiumPhase 1
Cinclus Pharma
Cinclus PharmaSweden - Stockholm
1 program
1
linaprazan glurate 25 mg QDPhase 11 trial
Active Trials
NCT05742984Completed75Est. Apr 2023
Takeda
TakedaTOKYO, Japan
1 program
Prevacid SolutabsN/A1 trial
Active Trials
NCT00624546Terminated24Est. Jan 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GenomicsNeobianacid®
AstraZenecaesomeprazole
AstraZenecaAntacids
AstraZenecaOmeprazole
Cinclus Pharmalinaprazan glurate 25 mg QD
AstraZenecaAn Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease
TakedaPrevacid Solutabs
AstraZenecaGastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs)
AstraZenecaCanadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD
AstraZenecaLIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
AstraZenecaEpidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERD
AstraZenecaImpact of GERD on Daily Life (NIS)

Clinical Trials (12)

Total enrollment: 13,702 patients across 12 trials

NCT03238534GenomicsNeobianacid®

Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS

Start: Sep 2017Est. completion: Sep 2021275 patients
Phase 4Completed
NCT00444275AstraZenecaesomeprazole

Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients

Start: Mar 2007Est. completion: Oct 20083,029 patients
Phase 4Completed
NCT00295685AstraZenecaAntacids

Nexium 40mg Once Daily vs Prevacid 30mg Twice a Day for Control of Severe GERD

Start: Oct 2005Est. completion: Dec 200750 patients
Phase 4Completed
NCT00256737AstraZenecaOmeprazole

Sopran - Omeprazole Treatment Versus Surgery

Start: Jan 1998Est. completion: Oct 2005219 patients
Phase 3Completed
NCT05742984Cinclus Pharmalinaprazan glurate 25 mg QD

Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects

Start: Jan 2023Est. completion: Apr 202375 patients
Phase 1Completed
NCT01134367AstraZenecaAn Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease

An Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease

Start: May 2010Est. completion: Dec 20101,000 patients
N/ACompleted
NCT00624546TakedaPrevacid Solutabs

Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD

Start: Jan 2009Est. completion: Jan 201424 patients
N/ATerminated
NCT00688675AstraZenecaGastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs)

Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments

Start: Feb 2008Est. completion: Aug 20082,912 patients
N/ACompleted
NCT00634023AstraZenecaCanadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD

Canadian, Multi-Centre Study of Symptom Burden and Clinical Management in Subjects With GERD

Start: Jan 2008Est. completion: May 2008500 patients
N/ACompleted
NCT00567619AstraZenecaLIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)

LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)

Start: Jul 2007900 patients
N/ACompleted
NCT00524355AstraZenecaEpidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERD

Epidemiological Study to Assess the Symptoms and Patterns of Diagnosis and Treatment of GERD

Start: Mar 2007Est. completion: Nov 20072,717 patients
N/ACompleted
NCT00545883AstraZenecaImpact of GERD on Daily Life (NIS)

Impact of GERD on Daily Life (NIS)

Start: Jun 2006Est. completion: Mar 20082,001 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space